Group 1 - The article emphasizes the importance of having at least 30 stocks for a well-diversified portfolio, suggesting a focus on diversification in investment strategies [1] - Leo Nelissen is identified as an analyst specializing in major economic developments related to supply chains, infrastructure, and commodities, indicating a focus on these sectors for investment opportunities [1] - The iREIT®+HOYA Capital team aims to provide insightful analysis and actionable investment ideas, particularly emphasizing dividend growth opportunities, which may attract income-focused investors [1] Group 2 - The article does not provide specific financial data or performance metrics related to companies or industries [2][3]

Agree Realty We screened our 24/7 Wall Street research database for quality companies rated Buy at major Wall Street firms that paid monthly dividends. Five seem like great ideas for Baby Boomer passive income-oriented investors seeking upside appreciation. All are rated Buy at the top Wall Street firms we cover. Why do we cover monthly dividend stocks? Passive income is characterized by its ability to generate revenue without the earner's continuous active effort, making it a desirable financial strategy f ...

Group 1 - The investment group High Yield Landlord is offering new members a promotion of $100 off and a 30-day money-back guarantee to attract new investors at the start of 2026 [1] - High Yield Landlord has released its Top Picks for 2026, indicating a strategic focus on identifying promising investment opportunities for the upcoming year [1] - Jussi Askola, the President of Leonberg Capital, leads the High Yield Landlord group, which provides real-time insights into REIT investments and includes features like multiple portfolios and direct access to analysts [2] Group 2 - Jussi Askola has a strong background in REIT investing, having authored award-winning academic papers and built relationships with top REIT executives, enhancing the credibility of the investment group [2] - The group offers three distinct portfolios: core, retirement, and international, catering to different investment strategies and goals [2]

Core Insights - Agree Realty Corp. is a real estate investment trust focused on net-leased retail properties in the U.S., targeting leading omni-channel retail tenants [1] Financial Performance - The company reported Q3 2025 earnings with FFO of $1.10, exceeding the consensus estimate of $1.07, and revenues of $183.19 million, surpassing the consensus of $177.88 million [4] - For Q4 2025, analysts expect EPS to be $0.71, a decrease from $1.04 in the prior-year period, while quarterly revenue is projected to be $188.33 million, an increase from $160.73 million a year earlier [2] Dividend Information - Agree Realty's dividend yield stands at 4.18%, with a total of $3.14 per share paid in dividends over the last 12 months [3] - To generate an income of $100 per month from dividends, an investment of approximately $28,708 is required, based on the current dividend yield [5][6] Guidance - The company adjusted its full-year 2025 AFFO per share guidance to a range of $4.31 to $4.33, compared to the previous range of $4.29 to $4.32 [4]

Core Insights - Biocytogen's partner IDEAYA Biosciences has received FDA IND clearance for IDE034, a bispecific antibody-drug conjugate targeting B7H3 and PTK7, marking a significant milestone in its clinical development [1][2][3] Group 1: Product Development - IDE034 is a bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and licensed to IDEAYA in July 2024 [2] - The IND clearance allows IDEAYA to initiate a Phase 1 clinical trial, with patient enrollment expected to begin in Q1 2026, focusing on solid tumors expressing B7H3 and PTK7 [1][3] - Preclinical studies indicate that IDE034 monotherapy shows strong anti-tumor activity, inducing deep and durable tumor regressions in multiple tumor models [3] Group 2: Clinical Strategy - IDEAYA plans to explore combination strategies with its PARG inhibitor IDE161 to enhance the durability of response, with additional preclinical data to be presented at a major medical conference in H1 2026 [3] - B7H3 and PTK7 are co-expressed in various cancers, with expression rates of approximately 30% in lung, 46% in colorectal, and 27% in head and neck cancers, indicating broad clinical potential for IDE034 [3] Group 3: Company Capabilities - The IND clearance validates Biocytogen's RenLite platform and proprietary linker-payload technologies, showcasing its capabilities in bispecific ADC discovery and development [2][3] - Biocytogen continues to provide high-quality source antibodies through its RenBiologics platform to support clinical translation and is actively seeking additional early-stage assets for licensing opportunities [4]

Core Insights - Agree Realty Corporation (ADC) is identified as a high growth stock with an average price target suggesting a nearly 10% upside, while the highest target indicates a potential upside of 22% [1][2] - Wells Fargo has reiterated a Buy recommendation for ADC with a price target of $83 as of November 25 [1] Financial Update - On November 18, Agree Realty completed an unsecured $350 million term loan with a 5.5-year maturity due in May 2031, which includes an accordion feature allowing for an additional $500 million borrowing [2] - The company has set up $350 million in forward-starting swaps to lock in the SOFR rate, resulting in a fixed interest rate of 4.02% for the new term loan [2] - The total liquidity of Agree Realty is reported at $2.2 billion, with no material debt maturities until 2028, enhancing its financial stability [3] Company Overview - Agree Realty Corporation operates as a real estate investment trust (REIT) focused on acquiring and developing net-leased properties for major retail brands [3]

Core Insights - ADC Therapeutics announced updated data from the LOTIS-7 Phase 1b trial, showing ZYNLONTA® combined with glofitamab (COLUMVI®) achieved an 89.8% overall response rate (ORR) and a 77.6% complete response (CR) rate in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) [1][2] Company Overview - ADC Therapeutics is a global leader in antibody drug conjugates (ADCs), focusing on innovative treatments for patients with hematological malignancies [2] - The company is headquartered in Lausanne, Switzerland, with operations in London and New Jersey [2] Clinical Trial Highlights - The LOTIS-7 trial is designed to evaluate the safety and efficacy of ZYNLONTA in combination with various agents, including glofitamab, in patients with B-cell non-Hodgkin lymphoma [1] - As of November 17, 2025, 49 patients were efficacy-evaluable, with a minimum of 6 months follow-up [1] - The trial aims to complete enrollment of approximately 100 patients by the first half of 2026, with full data expected to be shared at a medical meeting and submitted for publication by the end of 2026 [1] Efficacy Data - The best overall response rate (ORR) was 89.8%, with 44 out of 49 patients responding [1] - The complete response (CR) rate was 77.6%, with 33 of the 38 patients who achieved CR remaining in that state at the data cutoff [1] - In the subgroup of 24 relapsed patients, the ORR was 100% and the CR rate was 91.7% [1] - Among 25 primary refractory patients, the ORR was 80% and the CR rate was 64% [1] Safety Profile - The combination treatment was generally well tolerated, with a manageable safety profile [1] - Grade 3 or higher treatment-emergent adverse events (TEAEs) included neutropenia (32.7%), GGT increased (16.3%), and anemia (10.2%) [1] - Cytokine release syndrome (CRS) occurred in 36.7% of patients, with varying severity across dose levels [1] Future Plans - The company plans to assess regulatory and compendia strategies for ZYNLONTA and its combinations [1] - ADC Therapeutics is also advancing a next-generation PSMA-targeting ADC, leveraging its expertise in ADC development [2]

Group 1 - The article discusses the perspective of a dividend-focused investor considering which stocks to include in a portfolio if starting fresh today, particularly for retirees [1] - The investor emphasizes a preference for quality over quantity in selecting dividend-paying companies, aiming to build a portfolio that can supplement retirement income within the next 5-7 years [2] - The investor's goal is to assist lower and middle-class workers in building high-quality, dividend-paying investment portfolios to achieve financial independence [2] Group 2 - The article includes a disclosure of a beneficial long position in specific stocks such as ADC, VICI, and VZ, indicating a personal investment interest [3] - It is noted that the article is not providing financial advice and encourages readers to conduct their own due diligence [2][4] - The article highlights that past performance is not indicative of future results, and no specific investment recommendations are made [4]

Core Insights - Companies with a strong history of dividend payments and increases are attractive to income-focused investors, with Philip Morris, Rexford Industrial Realty, and Agree Realty being notable examples [1] Philip Morris - Philip Morris International Inc. has raised its dividends for 17 consecutive years, with the latest increase on Sept. 19 raising the quarterly payout from $1.35 to $1.47 per share, resulting in an annual figure of $5.88 per share [3] - The current dividend yield for Philip Morris is 3.77% [3] - The company's annual revenue as of Sept. 30 is $39.99 billion, with Q3 2025 revenues reported at $10.85 billion and EPS of $2.24, both exceeding consensus estimates [3] Rexford Industrial Realty - Rexford Industrial Realty Inc. has increased its dividends for 12 consecutive years, with a recent 3% increase on Feb. 5 to $0.43 per share, equating to an annual figure of $1.72 per share [5] - The company maintained its dividend payout at the same level in the latest announcement on Oct. 13, with a current dividend yield of 4.21% [5] - The annual revenue as of Sept. 30 is $997.93 million, with Q3 2025 revenues of $246.76 million, which missed the consensus estimate of $249.71 million, while EPS of $0.60 exceeded the consensus of $0.42 [6] Agree Realty - Agree Realty Corp. is a real estate investment trust focused on acquiring and developing properties leased to leading omnichannel retail tenants [7]

Core Viewpoint - Agree Realty Corporation (ADC) is a strong real estate investment trust (REIT) with a solid financial foundation and consistent dividend payments, making it an attractive investment option for income-seeking investors [1][2][5]. Financial Performance - ADC's asset base exceeds $9 billion, showcasing its financial strength and stability [2][6]. - The company has a market capitalization of approximately $8.11 billion and a trading volume of 532,452 shares, indicating its significant presence in the REIT sector [5]. Stock Performance - As of November 25, 2025, ADC was priced at $75.19, with Wells Fargo maintaining an "Overweight" rating and increasing its price target from $81 to $83 [1][6]. - Currently, ADC is priced at $75.18, reflecting a 1.14% increase with a price change of $0.85, and has shown volatility over the past year with a high of $79.65 and a low of $67.58 [4]. Dividend and Preferred Stock - ADC has a 30-year history of consistent dividend payments, appealing to investors seeking reliable income [2][6]. - The preferred stock, ADC.PR.A, offers a yield of 5.88% and is rated BBB-/BBB/Baa2, making it an attractive option for conservative investors [3][6].